期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 83, 期 3, 页码 386-389出版社
WILEY
DOI: 10.1038/sj.clpt.6100384
关键词
-
资金
- NIBIB NIH HHS [R21 EB005252, R21 EB005252-03, EB005252, R21 EB005252-02] Funding Source: Medline
- NINDS NIH HHS [R01 NS045062, R01 NS045062-03, NS045062, R01 NS045062-04] Funding Source: Medline
- NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R21EB005252] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045062] Funding Source: NIH RePORTER
Human embryonic stem (ES) cells are an attractive tool for cell-based therapies because of their limitless capacity for proliferation and their ability to differentiate into all cell types of the body. However, these features introduce certain unique risks that must be considered in developing transplantation strategies for clinical use. We outline these risks and examine current approaches to address them, both before and after transplantation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据